Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.58 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | DGKA | P23743 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14009796 | 0.98 | NAAA (0.61) | NAAARAD52NPSR1FAAHDGKA | |
| SCHEMBL2909889 | 0.98 | NAAA (0.61) | NAAARAD52NPSR1FAAHDGKA | |
| SCHEMBL13248688 | 0.98 | NAAA (0.61) | NAAARAD52NPSR1FAAHDGKA | |
| SCHEMBL2910617 | 0.95 | NAAA (0.50) | NAAARAD52NPSR1FAAHDGKA | |
| SCHEMBL27877633 | 0.89 | NAAA (0.47) | NAAARAD52NPSR1FAAHDGKA | |
| SCHEMBL2910006 | 0.89 | NAAA (0.47) | NAAARAD52NPSR1FAAHDGKA | |
| SCHEMBL2910833 | 0.88 | NAAA (0.40) | NAAADGKADNM1HCAR2ALDH1A1 | |
| SCHEMBL14009789 | 0.88 | NAAA (0.50) | NAAARAD52NPSR1FAAHDGKA | |
| SCHEMBL17812826 | 0.88 | NAAA (0.50) | NAAARAD52NPSR1FAAHDGKA | |
| SCHEMBL17812568 | 0.88 | NAAA (0.50) | NAAARAD52NPSR1FAAHDGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4385529-A2 | DEVICES FOR CONTROLLED DELIVERY | Femasys, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-3787533-B1 | DEVICES FOR CONTROLLED DELIVERY | FEMASYS INC (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20230390105-A1 | METHODS AND DEVICES FOR CONTROLLED DELIVERY | POINTILLIST GLOBAL MACRO SERIES OF POINTILLIST PARTNERS LLC | 2023-12-07 | — | — | US | disclosed |
| US-20230329900-A1 | METHODS AND DEVICES FOR CONTROLLED DELIVERY | FEMASYS INC. | 2023-10-19 | — | — | US | disclosed |
| US-11744729-B2 | Methods and devices for controlled delivery | FEMASYS INC. (US) | 2023-09-05 | — | — | US | disclosed |
| EP-3787533-A1 | METHODS AND DEVICES FOR CONTROLLED DELIVERY | Femasys, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20190336325-A1 | METHODS AND DEVICES FOR CONTROLLED DELIVERY | FEMASYS INC. | 2019-11-07 | — | — | US | disclosed |
| WO-2018148453-A1 | METHODS AND COMPOSITIONS COMPRISING BIODEGRADABLE CYANOACRYLATES | FEMASYS, INC. (US) | 2018-08-16 | — | — | WO | disclosed |
| CN-102503824-B | Process for synthesizing long-chain acylated citrate | NANJING UNIVERSITY OF TECHNOLOGY | 2014-12-10 | — | — | CN | disclosed |
| US-20130089505-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | VALOR MEDICAL, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| CN-102503824-A | Process for synthesizing long-chain acylated citrate | NANJING UNIVERSITY OF TECHNOLOGY | 2012-06-20 | — | — | CN | disclosed |
| EP-2219553-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | Valor Medical, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20090257976-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | VALOR MEDICAL, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| WO-2009064698-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | VALOR MEDICAL, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130089505-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | MMAB, CBL, ECPAS | NAAA 1050/4885RAD52 368/4885NPSR1 4597/4885 |
| US-20090257976-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | MMAB, CBL, ECPAS | NAAA 1050/4885RAD52 368/4885NPSR1 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.